Review: inhaled insulin provided better glycaemic control than oral hypoglycaemic agents but not subcutaneous insulin

2007 ◽  
Vol 12 (2) ◽  
pp. 52-52
Author(s):  
Z. Punthakee
Keyword(s):  
Glycaemic Control ◽  
Subcutaneous Insulin ◽  
Oral Hypoglycaemic Agents ◽  
Inhaled Insulin ◽  
Hypoglycaemic Agents

scholarly journals Diabetes mellitus in dialysis and renal transplantation

2021 ◽  
Vol 12 ◽  
pp. 204201882110486
Author(s):  
Eyal Ben-David ◽  
Richard Hull ◽  
Debasish Banerjee
Keyword(s):  
Diabetes Mellitus ◽  
Glycaemic Control ◽  
Kidney Transplant ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Oral Hypoglycaemic Agents ◽  
Maintenance Haemodialysis ◽  
Hypoglycaemic Agents ◽  
Tissue Sensitivity ◽  
End Stage

Diabetes mellitus is the commonest cause of end-stage kidney failure worldwide and is a proven and significant risk factor for the development of cardiovascular disease. Renal impairment has a significant impact on the physiology of glucose homeostasis as it reduces tissue sensitivity to insulin and reduces insulin clearance. Renal replacement therapy itself affects glucose control: peritoneal dialysis may induce hyperglycaemia due to glucose-rich dialysate and haemodialysis often causes hypoglycaemia due to the relatively low concentration of glucose in the dialysate. Autonomic neuropathy which is common in chronic kidney disease (CKD) and diabetes increases the risk for asymptomatic hypoglycaemia. Pharmacological options for improving glycaemic control are limited due to alterations to drug metabolism. Impaired glucose tolerance and diabetes are also common in the post-kidney-transplant setting and increase the risk of graft failure and mortality. This review seeks to summarise the literature and tackle the intricacies of glycaemic management in patients with CKD who are either on maintenance haemodialysis or have received a kidney transplant. It outlines changes to glycaemic targets, monitoring of glycaemic control, the use of oral hypoglycaemic agents, the management of severe hyperglycaemia in dialysis and kidney transplantation patients.

Insulin Initiation and Concomitant OHA (Oral Hypoglycaemic Agents) in Treatment of Diabetes Mellitus—Results of the Indian Human Insulin Registry (INHIRIT)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2293-PUB ◽  
Author(s):  
VEERANNA KARADI ◽  
DILIP PAWAR ◽  
SARAH JABEEN ◽  
SANDEEP S. ◽  
SAPTARSHI BOSE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Human Insulin ◽  
Insulin Initiation ◽  
Oral Hypoglycaemic Agents ◽  
Hypoglycaemic Agents ◽  
Treatment Of Diabetes
Sign in / Sign up

Export Citation Format

Share Document